RET fusion or mutation

Approved therapies

Approvals in the United States (FDA) and the European Union (EMA), one row per drug, regimen and tumour type. Where we have them, the pivotal trial's results and side effects are shown under each therapy, from the official label. Results from different trials are not directly comparable: patients, earlier treatments and comparators differ.

Companion diagnostic tests

Tests the FDA has approved to select patients for a specific therapy. Other validated tests are often used in practice, especially in Europe.

Drugs in active trials

Targeted drugs, antibody-drug conjugates and immunotherapies in active trials on this page, approved ones first, then by the furthest phase reached. Chemotherapy and supportive medicines are left out. "Not yet classified" means an early drug known only by its code.

25 of 50 drugs shown

Show all 50 drugs

Upcoming readouts

Active phase 2 and 3 trials whose primary completion date falls in the next 12 months: the date the main results are due to be collected, according to the sponsor. Results are usually published months later, and these dates often slip.

Companies

Industry sponsors leading active trials, by number of trials. Each square is one trial, shaded by phase.

1. Eli Lilly 7
2. Rigel Pharmaceuticals 1
3. Hansoh Pharma 1
4. Roche 1
5. Ellipses Pharma 1
6. Kelun-Biotech 1
7. Taiho Pharmaceutical 1
8. Applied Pharmaceutical Science 1
9. BioNTech 1
10. CSPC 1
11. ScinnoHub Pharmaceutical 1
12. Shenzhen NewDEL Biotech 1

Phase 1 Phase 2 Phase 3 Phase 4 No phase

Trials

Matched automatically from registry text, so a few trials may only mention RET fusion or mutation rather than require it. Check the quoted criterion, and the registry entry before relying on a match.

42 of 73 trials shown

1. A Study of Selpercatinib (LY3527723) in Participants With Rearranged During Transfection (RET)-Altered Cancers in India

   Not yet recruiting Phase 4 Eli Lilly Started 2026Primary completion 2029-10 NCT07822880

   selpercatinib FDA EU

   Participants with one of the following RET-altered cancers:

   Thyroid Neoplasms, Carcinoma, Non-Small-Cell Lung

2. Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors

   Recruiting Phase 4 Rigel Pharmaceuticals Started 2026Primary completion 2027-07 NCT07704658

   pralsetinib FDACYP3A4, CYP2C8, and CYP2C9 substrates, and hormonal contraceptive

   … has relapsed after, or is not responsive to, standard therapies and harbors an oncogenic RET fusion or mutation as determined by a validated test.

   NSCLC (Non-small Cell Lung Cancer), Thyroid Cancer, Solid Tumor Malignancies, Advanced Malignancies

3. Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study

   Not yet recruiting Phase 4 Fujian Medical University Started 2025Primary completion 2027-12 NCT07010393

   dabrafenibtrametinibselpercatinib FDA EUpralsetinib FDAlenvatiniblarotrectinibanlotinibpembrolizumabsintilimabcabozantinibBemosuzumab

   RET gene fusion

   Thyroid Neoplasms

4. A Prospective, Single-center, Non-randomized, Interventional Study on the Effectiveness and Safety of Combined Immunotargeted Therapy in Patients With Metastatic Non-small Cell Cancer With a RET Gene Translocation

   Recruiting Phase 3 EuroCityClinic Started 2026Primary completion 2028-08 NCT07809256

   lenvatinibpembrolizumab

   Have a confirmed RET gene rearrangement, identified using a validated molecular test, such as next-generation sequencing (NGS), p…

   NSCLC (Non-small Cell Lung Cancer)R

5. Phase III Study of SY-5007, a RET Inhibitor, in Patients With Locally Advanced or Metastatic RET Fusion-positive NSCLC

   Active, not recruiting Phase 3 Shouyao Holdings Started 2023Primary completion 2025-04 NCT06031558

   SY-5007

   Previous tumor tissue or blood samples are confirmed as RET fusion positive by local laboratory testing. b.

   Non-Small Cell Lung Cancer

6. A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

   Active, not recruiting Phase 3 Eli Lilly Started 2021Primary completion 2026-01 NCT04819100

   selpercatinib FDA EU

   Must have an activating RET gene fusion in tumor based on polymerase chain reaction (PCR), next generation sequencing (NGS), or a…

   Carcinoma, Non-Small-Cell Lung

7. A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

   Active, not recruiting Phase 3 Eli Lilly Started 2020Primary completion 2023-05 NCT04211337

   selpercatinib FDA EUcabozantinibvandetanib

   A defined/acceptable RET gene alteration identified in a tumor, germline deoxyribonucleic acid (DNA) or blood sample.

   Medullary Thyroid Cancer

8. A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

   Active, not recruiting Phase 3 Eli Lilly Started 2020Primary completion 2023-05 NCT04194944

   selpercatinib FDA EUcarboplatincisplatinpemetrexedpembrolizumab

   A RET gene fusion in tumor and/or blood from a qualified laboratory.

   Non-Small Cell Lung Cancer

9. Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer

   Active, not recruiting Phase 3 M.D. Anderson Cancer Center Started 2017Primary completion 2027-03 NCT03391869

   ipilimumabnivolumab

   Also, note that patients with ROS1/RET alterations can be enrolled, as tyrosine kinase inhibitor such as crizotinib aren't established as fi…

   Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8

10. PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC

    Recruiting Phase 2 Guangdong Association of Clinical Trials Started 2026Primary completion 2027-12 NCT07416058

    iparomlimab and tuvonralimabpemetrexedbevacizumab

    ALK, ROS1, RET fusions

    Lung Adenocarcinoma

11. Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)

    Recruiting Phase 2 Children's Hospital of Philadelphia Started 2024Primary completion 2030-11 NCT06458036

    selpercatinib FDA EU

    Identification of an activating RET gene alteration (fusion or mutation).

    Differentiated Thyroid Cancer, Pediatric Cancer, Cancer, Cancer, Thyroid

12. A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

    Recruiting Phase 2 Hansoh Pharma Started 2023Primary completion 2027-08 NCT06147570

    HS-10365 capsules

    …gically or cytologically confirmed diagnosis of locally advanced or metastatic NSCLC with RET fusion-positive, including recurrent or initial diagnosed Stage IIIB-IIIC/IV NSCLC that is not s…

    Status may be outdated, last updated 2023-11-27Nonsmall Cell Lung Cancer

13. The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC

    Recruiting Phase 1/2 Hunan Province Tumor Hospital Started 2023Primary completion 2026-12 NCT06109558

    osimertinib

    Cohort A：MET amplification,(by FISH, NGS or IHC) Cohort B：RET fusion.

    Status may be outdated, last updated 2024-05-30Non Small Cell Lung Cancer, RET Gene Mutation, MET Amplification, EGF-R Positive Non-Small Cell Lung Cancer

14. Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC

    Recruiting Phase 2 Massachusetts General Hospital Started 2023Primary completion 2025-03 NCT05668962

    selpercatinib FDA EUSodium Iodine I-131rhTSH

    …astic thyroid cancer that is metastatic and/or unresectable AND harbors a known oncogenic RET gene fusion, performed in a Clinical Laboratory Improvement Amendments (CLIA)-certified or equivalent…

    Thyroid Cancer, Thyroid Carcinoma, Metastatic Thyroid Cancer, Follicular Thyroid Cancer

15. A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies

    Recruiting Phase 1/2 Ellipses Pharma Started 2022Primary completion 2027-03 NCT05443126

    lunbotinibPlatinum chemotherapypemetrexed

    Must be ≥18 years of age, with documented RET-altered NSCLC

    NSCLC

16. Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial

    Active, not recruiting Phase 2 National Cancer Institute (NCI) Started 2021Primary completion 2024-09 NCT04320888

    selpercatinib FDA EU

    …e Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial

    Hematopoietic and Lymphatic System Neoplasm, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma

17. A Study of KL590586 in Patients With Advanced Solid Tumors

    Active, not recruiting Phase 1/2 Kelun-Biotech Started 2021Primary completion 2026-12 NCT05265091

    KL590586 Capsule

    …cs And Effectiveness Of KL590586 Capsules In Patients With Advanced Solid Tumors Carrying RET Fusion Or Mutant Genes

    Advanced Solid Tumor

18. Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer

    Active, not recruiting Phase 2 M.D. Anderson Cancer Center Started 2021Primary completion 2027-11 NCT04759911

    selpercatinib FDA EU

    Having an activating RET gene alteration (fusion or mutation).

    Malignant Thyroid Gland Neoplasm, Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma, Thyroid Gland Anaplastic Carcinoma

19. A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

    Recruiting Phase 2 Roche Started 2020Primary completion 2026-11 NCT04302025

    alectinibentrectinibvemurafenibcobimetinibpralsetinib FDAatezolizumabSBRTChemotherapydivarasib

    BRAF V600 mutation, RET fusion, PD-L1 expression in ≥ 1% tumor cells as determined by Food and Drug Administration (FDA)…

    Non-small Cell Lung Cancer

20. Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)

    Active, not recruiting Phase 2 SWOG Cancer Research Network Started 2020Primary completion 2026-12 NCT04268550

    selpercatinib FDA EU

    …igned to S1900B based on biomarker analysis of tissue and/or blood and determined to have RET fusion-positive NSCLC as defined here:

    Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8

21. Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities

    Recruiting Phase 1/2 Taiho Pharmaceutical Started 2020Primary completion 2030-03 NCT04683250

    TAS0953/HM06

    Patient with RET gene fusion :

    RET-altered Non Small Cell Lung Cancer, RET-altered Solid Tumors

22. A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation

    Active, not recruiting Phase 2 Eli Lilly Started 2020Primary completion 2021-03 NCT04280081

    selpercatinib FDA EU

    Evidence of a RET gene alteration in tumor and/or blood.

    Solid Tumor, Medullary Thyroid Cancer

23. A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors

    Active, not recruiting Phase 1/2 Eli Lilly Started 2019Primary completion 2024-11 NCT03899792

    selpercatinib FDA EU

    Evidence of an activating RET gene alteration in the tumor and/or blood

    Medullary Thyroid Cancer, Infantile Myofibromatosis, Infantile Fibrosarcoma, Papillary Thyroid Cancer

24. A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)

    Active, not recruiting Phase 1/2 Eli Lilly Started 2017Primary completion 2025-02 NCT03157128

    selpercatinib FDA EU

    A RET gene alteration is not required initially.

    Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor

25. Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

    Active, not recruiting Phase 2 National Cancer Institute (NCI) Started 2017Primary completion 2021-06 NCT02867592

    cabozantinib

    …ating mutation, MET translocation, MET exon skipping mutations, activating RET mutations, RET rearrangement, overexpression or activation of AXL)

    Adrenal Cortical Carcinoma, Alveolar Soft Part Sarcoma, Central Nervous System Neoplasm, Childhood Clear Cell Sarcoma of Soft Tissue

26. Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity

    Recruiting Phase 2 Memorial Sloan Kettering Cancer Center Started 2012Primary completion 2027-07 NCT01639508

    cabozantinib

    Group A: KIF5B/RET or related variant RET fusions.

    Non-Small Cell Lung Cancer

27. Study of SNH-118110 in Advanced Solid Tumors

    Not yet recruiting Phase 1 ScinnoHub Pharmaceutical Started 2026Primary completion 2027-06 NCT07649200

    SNH-118110 Soft Capsules

    Dose-escalation phase: Patients with advanced solid tumors harboring a RET gene alteration who have failed standard therapy or are intolerant to standard therapy.

    Solid Tumors

28. An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of ND-003 in Patients With Advanced Solid Cancers

    Enrolling by invitation Phase 1 Shenzhen NewDEL Biotech Started 2024Primary completion 2028-06 NCT06169579

    ND-003 tablets

    However, in the dose expansion phase, subjects must have confirmed NTRK or RET gene fusion/mutation (histologic or cytological genetic testing results are acceptable) .

    Advanced Solid Tumor

29. A Study of APS03118 in Advanced Solid Tumors Harboring RET Mutations or Fusions

    Active, not recruiting Phase 1 Applied Pharmaceutical Science Started 2023Primary completion 2026-10 NCT05653869

    APS03118

    …firmation of unresectable locally advanced or metastatic solid tumors harboring oncogenic RET mutations or fusions confirmed by NGS.

    RET-altered Solid Tumors

30. Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

    Recruiting Phase 1 BioNTech Started 2022Primary completion 2030-02 NCT05142189

    BNT116cemiplimabdocetaxelcarboplatinpaclitaxelgotistobartanti-B7-H3 antibody conjugated to topoisomerase I inhibitoranti-HER3 antibody conjugated to topoisomerase I inhibitorBispecific antibody for PD-L1 and VEGF-AosimertinibALK-inhibitor or RET-inhibitor

    Participants' NSCLC must have ALK rearrangement or RET rearrangement.

    Non-Small Cell Lung Cancer

31. A Real-world Study of Pralsetinib Combined With Leucogen in the Treatment of RET Fusion-positive NSCLC

    Not yet recruiting No phase Fudan University Started 2026Primary completion 2027-12 NCT07418879

    pralsetinib FDALeucogen

    (3)RET fusion-positive;

    Non-small Cell Lung Cancer, RET Fusion, Pralsetinib

32. Perioperative Targeted Therapy in Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer With Rare Driver Mutations

    Not yet recruiting Phase 2 Shanghai Zhongshan Hospital Started 2026Primary completion 2030-06 NCT07829744

    …umented EGFR exon 20 insertion, ALK fusion, ROS1 fusion, MET exon 14 skipping alteration, RET fusion, or KRAS G12C mutation.

    Broad match: RET fusion or mutationLung Cancer (NSCLC)

33. Phase II Clinical Study of JS207 (PD-1/VEGF Bispecific Antibody) Combination Therapies in Patients With Driver Gene-Positive, Advanced Non-Small Cell Lung Cancer After Failure of TKI Therapy

    Recruiting Phase 2 Shanghai Junshi Bioscience Started 2025Primary completion 2026-09 NCT06868836

    JS207pemetrexedcarboplatincisplatinJS212

    … ALK fusion, ROS1 fusion, BRAF V600E mutation, NTRK fusion, MET14 exon skipping mutation, RET fusion, KRAS G12C mutation, HER-2 mutation, EGFR 20 exon insertion mutation.

    Broad match: RET fusion or mutationNon-squamous Non-small Cell Lung Cancer

34. Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer Study

    Recruiting Phase 2 Sun Yat-sen University Started 2024Primary completion 2026-07 NCT06547203

    cetuximabtoripalimabirinotecan

    …ons including: RAS/BRAF V600E/PIK3CA/PTEN/EGFR (ECD), HER2 and MET amplification, and ALK/RET/NTRK1 gene fusions.

    Broad match: RET fusion or mutationStatus may be outdated, last updated 2024-08-09Colorectal Cancer Metastatic

35. Efficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases

    Recruiting Phase 2 Hunan Province Tumor Hospital Started 2024Primary completion 2026-12 NCT06440954

    pemetrexed

    EGFR mutant, ALK fusion, ROS1 fusion, and other oncogenic alterations including RET fusion, BRAF mutation, NTRK fusion, KRAS mutation was confirmed by an accredited local laborator…

    Broad match: RET fusion or mutationStatus may be outdated, last updated 2024-06-04Non-Small Cell Lung Cancer

36. Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.

    Recruiting Phase 2 Sun Yat-sen University Started 2024Primary completion 2027-11 NCT06563999

    sunvozertinibcrizotinibpralsetinib FDAlarotrectinibsavolitinibpyrotinibdabrafenibtrametinibglecirasibensartinib

    …ld have a rare mutation based on NGS, including mutations of EGFR exon20ins, ROS1 fusion, RET fusion, NTRK fusion, MET 14 exon, HER2, BRAF V600E, KRAS G12C, and ALK fusion.

    Broad match: RET fusion or mutationLung Cancer Stage III, Mutation

37. A Study of Avutometinib and Defactinib in People With Thyroid Cancer

    Recruiting Phase 2 Memorial Sloan Kettering Cancer Center Started 2023Primary completion 2027-08 NCT06007924

    avutometinibdefactinib

    …s) possess at least one of the following genetic alterations: RAS mutation, NF1 mutation, RET rearrangement, NTRK rearrangement, ALK rearrangement, Class 2 or 3 BRAF alterations (non-V600E/K mutati…

    Broad match: RET fusion or mutationThyroid Cancer

38. Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC

    Recruiting Phase 2 Guangdong Provincial People's Hospital Started 2023Primary completion 2024-12 NCT05800340

    toripalimabnab-paclitaxelpemetrexedcarboplatin

    …irmed diagnosis with Stage IIB-IIIB NSCLC which harbored rare driver alteration including RET fusions, BRAF (V600E or non-V600E but confirmed driver mutations), ERBB2 exon20 insertion, MET am…

    Broad match: RET fusion or mutationStatus may be outdated, last updated 2023-04-05Non-Small Cell Lung Cancer, RET Driver Mutation, BRAF V600 Mutation, Erb-B2 Receptor Tyrosine Kinase Exon 20 Mutation

39. The Efficacy and Safety of IBI363 in Solid Tumors

    Recruiting Phase 1/2 Hunan Province Tumor Hospital Started 2023Primary completion 2026-12 NCT06081907

    IBI363lenvatinib

    …tations, including but not limited to ROS1, BRAF V600E, METex14 skipping, HER2, NTRK, and RET fusion.

    Broad match: RET fusion or mutationStatus may be outdated, last updated 2024-05-30Advanced Solid Tumor

40. Surufatinib Combined With Toripalimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer

    Active, not recruiting Phase 2 Li Zhang, MD Started 2022Primary completion 2025-11 NCT05003037

    surufatinibtoripalimabpemetrexedcarboplatincisplatin

    …nfirm a pan-driver gene (including but not limited to EGFR mutation, ALK fusion, ROS1 and RET fusion

    Broad match: RET fusion or mutationNon Small Cell Lung Cancer

41. Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

    Active, not recruiting Phase 2 National Cancer Institute (NCI) Started 2013Primary completion 2015-08 NCT01708954

    cabozantiniberlotinib

    …) mutation, human epidermal growth factor receptor 2 (HER2) mutation, ret proto-oncogene (RET) rearrangement/fusion, or one not listed following approval by the study chair prior to registration

    Broad match: RET fusion or mutationRecurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7

42. A Clinical Study of SYS6023 in Patients With Advanced Solid Tumors

    Recruiting Phase 1 CSPC Started 2024Primary completion 2026-10 NCT07110883

    SYS6023

    …urotrophic Tyrosine Receptor Kinase (NTRK) fusion, Neurotrophic Tyrosine Receptor Kinase (RET) rearrangement, HER2 mutation, MET Proto-Oncogene（Met）exon14 skipping mutation, Met amplification, KRAS …

    Broad match: RET fusion or mutationAdvanced Solid Tumor

No trials match these filters.